702 related articles for article (PubMed ID: 16101165)
1. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study.
Syrjänen K; Naud P; Derchain S; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Hammes LS; Matos J; Gontijo R; Sarian L; Braganca J; Arlindo FC; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S
Anticancer Res; 2005; 25(5):3469-80. PubMed ID: 16101165
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.
Sarian LO; Derchain SF; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo R; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
J Med Screen; 2005; 12(3):142-9. PubMed ID: 16156945
[TBL] [Abstract][Full Text] [Related]
3. Conventional Pap smear and liquid-based cytology as screening tools in low-resource settings in Latin America: experience of the Latin American screening study.
Longatto-Filho A; Maeda MY; Erzen M; Branca M; Roteli-Martins C; Naud P; Derchain SF; Hammes L; Matos J; Gontijo R; Sarian LO; Lima TP; Tatti S; Syrjänen S; Syrjänen K
Acta Cytol; 2005; 49(5):500-6. PubMed ID: 16334026
[TBL] [Abstract][Full Text] [Related]
4. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.
Derchain SF; Sarian LO; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo RC; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
J Med Screen; 2008; 15(2):97-104. PubMed ID: 18573778
[TBL] [Abstract][Full Text] [Related]
5. Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology.
Longatto-Filho A; Naud P; Derchain SF; Roteli-Martins C; Tatti S; Hammes LS; Sarian LO; Eržen M; Branca M; de Matos JC; Gontijo R; Maeda MY; Lima T; Costa S; Syrjänen S; Syrjänen K
Virchows Arch; 2012 Jun; 460(6):577-85. PubMed ID: 22562132
[TBL] [Abstract][Full Text] [Related]
6. Smoking worsens the prognosis of mild abnormalities in cervical cytology.
Guarisi R; Sarian LO; Hammes LS; Longatto-Filho A; Derchain SF; Roteli-Martins C; Naud P; Erzen M; Branca M; Tatti S; Costa S; Syrjänen S; Bragança JF; Syrjänen K
Acta Obstet Gynecol Scand; 2009; 88(5):514-20. PubMed ID: 19308752
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
[TBL] [Abstract][Full Text] [Related]
8. Aided visual inspection with acetic acid (VIA) and HPV detection as optional screening tools for cervical cancer and its precursor lesions.
Bragança JF; Derchain SF; Sarian LO; Messias da Silva SM; Labatte S; Zeferino LC
Clin Exp Obstet Gynecol; 2005; 32(4):225-9. PubMed ID: 16440819
[TBL] [Abstract][Full Text] [Related]
9. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
[TBL] [Abstract][Full Text] [Related]
10. Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer.
Costa S; Sideri M; Syrjänen K; Terzano P; De Nuzzo M; De Simone P; Cristiani P; Finarelli AC; Bovicelli A; Zamparelli A; Bovicelli L
Acta Cytol; 2000; 44(3):310-8. PubMed ID: 10833984
[TBL] [Abstract][Full Text] [Related]
11. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
13. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
[TBL] [Abstract][Full Text] [Related]
14. Screening for cervical cancer in high-risk populations: DNA pap test or Hybrid Capture II test alone?
Miranda Pereira SM; Castelo A; Makabe S; Utagawa ML; Di Loreto C; Sakamoto Maeda MY; Marques JA; Santoro CL; Filho AL; Das Dores GB
Int J Gynecol Pathol; 2006 Jan; 25(1):38-41. PubMed ID: 16306782
[TBL] [Abstract][Full Text] [Related]
15. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population].
Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341
[No Abstract] [Full Text] [Related]
16. Screening capacity and cost-effectiveness of the human papillomavirus test versus cervicography as an adjunctive test to Pap cytology to detect high-grade cervical dysplasia.
Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():112-116. PubMed ID: 30682600
[TBL] [Abstract][Full Text] [Related]
17. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.
Salmerón J; Lazcano-Ponce E; Lorincz A; Hernández M; Hernández P; Leyva A; Uribe M; Manzanares H; Antunez A; Carmona E; Ronnett BM; Sherman ME; Bishai D; Ferris D; Flores Y; Yunes E; Shah KV
Cancer Causes Control; 2003 Aug; 14(6):505-12. PubMed ID: 12948281
[TBL] [Abstract][Full Text] [Related]
18. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear.
Monsonego J; Bohbot JM; Pollini G; Krawec C; Vincent C; Merignargues I; Haroun F; Sednaoui P; Monfort L; Dachez R; Syrjänen K
Gynecol Oncol; 2005 Oct; 99(1):160-8. PubMed ID: 16023184
[TBL] [Abstract][Full Text] [Related]
19. HPV testing with cytology triage for cervical cancer screening in routine practice.
Louvanto K; Chevarie-Davis M; Ramanakumar AV; Franco EL; Ferenczy A
Am J Obstet Gynecol; 2014 May; 210(5):474.e1-7. PubMed ID: 24373948
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
